Clinical Trials

**STUDY IS CLOSED at this site** This study is for patients with high-risk rhabdomyosarcoma, a type of cancer that’s hard to treat. Current treatments don’t work well for many patients. A medicine called vinorelbine has helped some people after treatment. This study will test if using vinorelbine earlier and for longer can help more patients survive. Two different drug plans will be tested. The study will also check if the new plan is safe and learn more about how the cancer works.

**STUDY IS CLOSED at this site** This study checks if kids and young adults with leukemia (CML) can safely stop their long-term medicine (TKIs). If their cancer has stayed low for 2 years, they may stop the medicine and get regular tests to watch for any return. The study also looks at how this affects their health and daily life.

(This study is closed at CAMC, for more information see the Clinical Trials NCT link below). This phase II/III trial compares the effect of adding radiation therapy to the usual maintenance therapy with atezolizumab versus atezolizumab alone in patients who have already received atezolizumab plus chemotherapy for the treatment of small cell lung cancer that has spread outside of the lung or to other parts of the body (extensive stage). Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Giving radiation therapy in addition to atezolizumab may extend the time without extensive small cell lung cancer growing or spreading compared to atezolizumab alone.

(Study at this site is closed to new patients, please see NCT website) Primary Mediastinal B-cell Lymphoma (PMBCL) is a rare and aggressive type of cancer that affects the lymphatic system, which is part of the body's immune system. It usually occurs in adolescents and young adults. PMBCL shares some biological features with another cancer called Hodgkin lymphoma, including changes in certain genes that can make the cancer harder to treat.

(The study at this site is closed, please see the NCT link if you are looking for more information) The ARST2031 study is a medical research trial designed to find better treatments for a rare and serious cancer called high-risk rhabdomyosarcoma (HR-RMS). This cancer affects muscles and is most common in children and teenagers. Even with strong treatments, many patients still have a low chance of staying cancer-free for 3 years.

Study is closed to new patients. This is a Phase III double blinded study that is studying male and female participants at least 18 years of age with MIBC clinical stage T2-T4aN0M0 who elect to receive CRT.

This phase III trial compares the combination of four drugs (daratumumab, bortezomib, lenalidomide and dexamethasone) to the use of a three drug combination (daratumumab, lenalidomide and dexamethasone). Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Chemotherapy drugs, such as lenalidomide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Daratumumab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Anti-inflammatory drugs, such as dexamethasone lower the body's immune response and are used with other drugs in the treatment of some types of cancer. Adding bortezomib to daratumumab, lenalidomide, and dexamethasone may be more effective in shrinking the cancer or preventing it from returning, compared to continuing on daratumumab, lenalidomide, and dexamethasone.

The purpose of this study is to compare the usual treatment (enzalutamide) alone to using rucaparib plus the usual treatment. The addition of rucaparib to the usual treatment could make patients live longer, or prevent cancer from growing or spreading for a longer time, or both.

Rhabdomyosarcoma is a type of cancer that occurs in the soft tissues in the body. This phase III trial aims to maintain excellent outcomes in patients with very low risk rhabdomyosarcoma (VLR-RMS) while decreasing the burden of therapy using treatment with 24 weeks of vincristine and dactinomycin (VA) and examines the use of centralized molecular risk stratification in the treatment of rhabdomyosarcoma.

This is a retrospective controlled survey-study to assess the safety of treating migraine with Nerivio during pregnancy and 3 months postpartum. We will compare migraine and pregnancy related health and baby health between women with migraine who treated migraine attacks during pregnancy with Nerivio (Nerivio group), to women with migraine who did not treat migraine attacks during pregnancy with Nerivio (control group). Nerivio group participants will be recruited from Theranica’s user base. Control group participants will be recruited by health care providers, including headache specialists and OBGYNs (study co-investigators). The study is fully electronic, including an e-eligibility questionnaire, an e-ICF, and an e-survey. Participants will be compensated for their time.